Торговать 4D Molecular Therapeutics Inc - FDMT CFD

Условия торговли

• Тип: CFD
• Спред: 0.10
• Корректировка финансирования овернайт по длинным позициям: -0.02160%
• Корректировка финансирования овернайт по коротким позициям: -0.00063%
• Время корректировки финансирования овернайт: 22:00 (UTC)
• Валюта: USD
• Минимальный объем торгов: 1
• Маржа: 50.00%
• Фондовая биржа: United States of America
• Торговая комиссия: 0%
• Плата за гарантированный стоп: 1%

Ключевые данные

• Пред. закрытие: 8.64
• Открыть: 8.37
• Изменение за 1 год: 41.39%
• Диапазон за день: 8.37 - 8.93

4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; Benitec; CRF; Roche; CFF; and AstraZeneca. The company was founded in 2013 and is headquartered in Emeryville, California.